Literature DB >> 2690329

Effect of omeprazole on gastric acid secretion and plasma gastrin in man.

L Olbe1, C Cederberg, T Lind, M Olausson.   

Abstract

Single doses of omeprazole inhibit pentagastrin-stimulated gastric acid secretion and almost complete inhibition can be achieved for 4-6 hours with a single dose of 80 mg. Acid secretion then slowly returns and reaches normal levels after 3-4 days. Omeprazole also dose-dependently inhibits basal acid secretion as well as acid secretion stimulated with histamine, peptone and modified sham feeding, with similar efficiency. During repeated once-daily dosing with an enteric-coated granule capsule formulation, inhibition of acid secretion increased initially, and stabilized within about 4 days. Dose-response studies in patients with duodenal ulcers and healthy subjects have shown that 20-40 mg/day results in a peak reduction (80-100%) of pentagastrin-stimulated acid secretion 6 hours after dose. Studies of 24-hour intragastric acidity in duodenal ulcer patients have shown that 4 weeks of treatment with omeprazole, 20 mg once daily, resulted in a reduction of median intragastric acidity by 97%, which was superior to the 57% median reduction achieved with ranitidine, 150 mg b.d., for 4 weeks in the same patients. During omeprazole treatment, fasting plasma gastrin increased in relation to the degree of inhibition of acid secretion. After discontinuation of treatment, plasma gastrin normalized. Treatment with omeprazole, 20 mg, increased 24-hour plasma gastrin to the same extent as after highly selective vagotomy. Long-term treatment with omeprazole, 20-40 mg, for up to 2 years has not been associated with any progressive rise in fasting plasma gastrin.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2690329     DOI: 10.3109/00365528909091240

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  10 in total

Review 1.  Treatment of gastroesophageal reflux disease.

Authors:  Michael Pettit
Journal:  Pharm World Sci       Date:  2005-12

2.  Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies.

Authors:  Chun-Sick Eom; Sang Min Park; Seung-Kwon Myung; Jae Moon Yun; Jeong-Soo Ahn
Journal:  Ann Fam Med       Date:  2011 May-Jun       Impact factor: 5.166

3.  Cough threshold in reflux oesophagitis: influence of acid and of laryngeal and oesophageal damage.

Authors:  L Benini; M Ferrari; C Sembenini; M Olivieri; R Micciolo; V Zuccali; G M Bulighin; F Fiorino; A Ederle; V L Cascio; I Vantini
Journal:  Gut       Date:  2000-06       Impact factor: 23.059

4.  Nizatidine versus placebo in gastroesophageal reflux disease. A six-week, multicenter, randomized, double-blind comparison. Nizatidine Gastroesophageal Reflux Disease Study Group.

Authors:  M L Cloud; W W Offen
Journal:  Dig Dis Sci       Date:  1992-06       Impact factor: 3.199

Review 5.  Risk of fracture and pneumonia from acid suppressive drugs.

Authors:  Chun-Sick Eom; Sang-Soo Lee
Journal:  World J Methodol       Date:  2011-09-26

Review 6.  Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.

Authors:  J G Hatlebakk; A Berstad
Journal:  Clin Pharmacokinet       Date:  1996-11       Impact factor: 6.447

7.  Duodenal bacterial overgrowth during treatment in outpatients with omeprazole.

Authors:  M Fried; H Siegrist; R Frei; F Froehlich; P Duroux; J Thorens; A Blum; J Bille; J J Gonvers; K Gyr
Journal:  Gut       Date:  1994-01       Impact factor: 23.059

8.  Omeprazole causes delay in gastric emptying of digestible meals.

Authors:  L Benini; G Castellani; E Bardelli; C Sembenini; M T Brentegani; S Caliari; I Vantini
Journal:  Dig Dis Sci       Date:  1996-03       Impact factor: 3.199

9.  Inhibition of gastric acid secretion with omeprazole affects fish specific dynamic action and growth rate: Implications for the development of phenotypic stomach loss.

Authors:  Kelsy Moffatt; Mark Rossi; Edward Park; Jon Christian Svendsen; Jonathan M Wilson
Journal:  Front Physiol       Date:  2022-09-27       Impact factor: 4.755

Review 10.  Progress with proton pump inhibition.

Authors:  N J Bell; R H Hunt
Journal:  Yale J Biol Med       Date:  1992 Nov-Dec
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.